FDA 483 OBSERVATION · #137 OF 1,923 MOST-CITED
Cleaning System
FDA cited this observation 216 times across 184 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The clean-in-place or automated cleaning system for food equipment did not reliably clean the surfaces it serves — spray coverage, flow, temperature, or chemical delivery was not adequate, or the system was assumed effective without proof. This falls under the sanitary-operations requirement of §117.35, with equipment design considerations reaching into §117.40.
Why FDA writes it — A CIP or automated cleaning system that leaves dead legs, shadowed surfaces, or under-dosed chemical creates a false sense of cleanliness while pathogens and allergen residues survive. FDA cites this because an unverified cleaning system lets contaminated equipment be released as clean, run after run.
- Define and record the critical cleaning parameters for the system — flow rate, spray-device coverage, temperature, chemical concentration, and cycle time.
- Verify each cycle meets those parameters (flow/pressure readings, temperature logs, conductivity or titration) and alarm or reject when it does not.
- Periodically inspect or swab hard-to-reach surfaces, dead legs, and gaskets to confirm the automated cycle actually reaches them.
- Requalify the cleaning system after equipment changes, and keep records that tie each release to a completed, in-spec cycle.
- Trust in the automated cycle without instrumentation or swabbing to prove the surfaces it cannot be seen cleaning are actually clean.
- Equipment design with dead legs and shadowed geometry that the cleaning system was never validated against.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 7.4× the rate of the average FDA-cited firm (57.6% vs 7.8%), across 184 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the to produce aseptic conditions.
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →